TIGRa Gene Activation Tool | Breakthrough for Clinical Use

A New Approach to Gene Activation

Precision gene regulation inside the human body represents a major shift in how doctors treat chronic illness. By turning protective genes up or down, medical professionals can theoretically prevent disease before it takes root. However, the standard tools currently used for these tasks, most notably the CRISPR system, suffer from a significant design flaw: they are too large to package and deliver into human cells. When scientists use viral vectors to deliver the DNA instructions for CRISPR, the length of those instructions often exceeds the available space, making complex therapies difficult to manage.

Stanford Medicine researchers have introduced a solution to this problem called TIGRa. This ultracompact gene activation tool fits inside viral vectors with enough room left over for additional components. Unlike CRISPR, which was initially adapted from a bacterial immune system designed to cut DNA, TIGRa originates from a system known as TIGR-Tas. Scientists identified TIGR-Tas only last year, and it appears to function as a guide for finding and activating specific DNA sequences. Because TIGRa is less than half the size of typical CRISPR-based activators, it avoids the space constraints that have historically limited gene therapies.

Testing TIGRa in the Lab

Zhiquan Liu, a postdoctoral scholar in ophthalmology and the lead author of the study, conducted a series of tests on various molecular prototypes before identifying TIGRa. He initially feared that reducing the size of the tool would result in lower performance. The results proved him wrong. TIGRa demonstrated high activation efficiency and, in some cases, outperformed existing CRISPR tools when targeting diverse genes. The research team even developed variants such as TIGRa-Pro and TIGRa-Ultra to offer more power in compact packages.

In laboratory settings, the team successfully used TIGRa to activate 12 different genes at once. They also used the tool to reprogram adult fibroblasts into induced pluripotent stem cells. This process requires the simultaneous activation of seven specific genes, a task that TIGRa handled with precision. By proving the system can target multiple sequences in one go, the researchers established a baseline for future applications that involve complex genetic disorders.

Vision Preservation and Future Scope

The most practical demonstration of the tool appeared in a mouse model focusing on retinal ganglion cells. These nerve cells are critical for vision and are often lost in cases of glaucoma. The researchers injected TIGRa into the eyes of mice, programming the tool to activate two protective genes known as CaMKIIa and CaMKIIb. After an induced injury, the untreated mice lost their vision. In contrast, those that received the TIGRa treatment retained about a third of their sight.

Four months after the initial treatment, the visual protection in the mice remained stable. This success suggests that TIGRa could eventually serve as a bridge toward treating human retinal degeneration. Yang Sun, a professor of ophthalmology and the study's senior author, noted that the eye serves as a prime testing ground because visual outcomes are measurable and immediate. Still, the path to clinical use involves further refinements to manage complex disease pathways.

Beyond eye care, the potential for TIGRa spans a wide range of conditions. The team has already filed a patent for the technology, anticipating its use in targeting genes related to heart, liver, and skin conditions, as well as neurodegeneration and cancer. The ability to deliver these tools efficiently is the core hurdle in modern gene therapy. With TIGRa, researchers now have a smaller, more versatile instrument to work with as they attempt to map and modify the genetic foundations of disease.